Abstract
Background Sudan is a large, landlocked, African country with a population of 46 million. It is considered a ‘least developed’ country, and coverage of essential health services is low. In April 2023 fighting broke out between the Sudanese Armed Forces and the paramilitary Rapid Support Forces. The conflict quickly escalated and has claimed 9,000 lives so far, with hundreds of thousands of people internally displaced. It is unclear exactly how the war has impacted Sudan’s already fragile health financing system.
Methods We conducted one-to-one semi-structured interviews with a purposive sample of experienced health financing policymakers and policy advisors working in- or with the Sudanese government. Five senior key informants were recruited using snowball sampling. Interview transcripts were analysed using thematic analysis, with reference to the WHO national health financing framework and Sparkes and colleagues’ political economy framework.
Findings Conflict has undoubtedly undermined Sudan’s ability to mobilise, allocate, and distribute financial resources. However, the existing health infrastructure was already so weak, and state funds so meagre, that the challenges posed by fighting were overshadowed by themes around Sudan’s underlying structural issues: out of pocket payments account for over 70% of all health expenditure; the existing national insurance scheme only covers a minority of the population; and there is unclear delineation of responsibilities between purchasers and providers and between the federal and state ministries of health. Major themes emerged around governance, revenue raising, risk pooling, purchasing and service delivery, and external donor funding.
Conclusions Investment in developing health financing capacity at the state level, implementation planning, blended financing for the national health insurance fund, donor coordination, and community mobilisation to agitate for greater risk pooling were identified as essential steps. Without robust mechanisms to pool risk and diversification of financing sources, it will not be possible to extend financial risk protection or basic health services to large sections of Sudan’s population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
LSHTM ethics committee approved this study on 7th August 2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
No data beyond those presented in the manuscript are available. This is to protect the interviewees.
